id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-N-5331-0886,FDA,FDA-2024-N-5331,Request for Extension from National Pain Advocacy Center,Other,Request for Extension,2025-05-05T04:00:00Z,2025,5,2025-05-05T04:00:00Z,,2025-05-21T20:31:53Z,,0,0,09000064b8cfca94
FDA-2024-N-5331-0003,FDA,FDA-2024-N-5331,Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Amendment of Notice—Extended-Release/Long-Acting Opioid Analgesic Postmarketing Requirement,Notice,Announcement,2025-04-21T00:00:00Z,2025,4,2025-04-21T00:00:00Z,2025-05-05T03:59:59Z,2025-05-13T09:00:48Z,2025-06787,0,0,0900006486aa4374
FDA-2024-N-5331-0001,FDA,FDA-2024-N-5331,"Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Notice
of Meeting; Establishment of a Public Docket; Request for Comments— Extended-Release/Long-Acting Opioid Analgesic Postmarketing Requirement",Notice,Request for Comments,2024-12-09T05:00:00Z,2024,12,2024-12-09T05:00:00Z,2025-02-05T04:59:59Z,2025-04-21T15:10:18Z,2024-28811,0,0,0900006486856209